Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $10.39M (cash outflow) fell 67.6% year over year, behind the -39.1% change in trailing-twelve-month net income. Sequentially, it fell 36.9% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.

Context

  • Net income amounted to 819.6% of revenue in FY2025, down 997.2 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$43.16M (-56.6%) for the fiscal year ending Dec 2026, a slowdown from the -21.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.39M-36.9% QoQ
Last fiscal yearDec 2025
-$99.5M-21.8% YoY
LTMMar 2026
-$77.8M-39.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-67.6%-38.0%+29.6 pp
1 year-21.8%-56.6%-34.9 pp
3-year CAGR-4.8%-41.1%-36.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(99.5M) USD
Year-over-year change
+21.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.1% is the 10th highest of 11, against a peer median of -13.0%.
  • Net income amounts to 465.3% of revenue for PRLD, versus a peer median of 889.5%.
PRLD Competitors
Net Income for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€340.16M EUR+84.7%+84.4%7587.8%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$133.22M USD-9.9%+14.2%1189.1%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$84.74M USD-216.1%+23.4%143627.1%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$83.01M USD-21.5%-9.9%36891.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$81.74M USD-14.2%-13.0%589.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$77.8M USD-39.1%-4.8%465.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M USD-6.4%-12.0%266.9%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$61.98M USD-35.7%-12.4%89.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.64M USD-17.6%+16.2%167.0%
IMRXImmuneering CorporationLTM Mar 2026$54.44M USD-11.9%+3.5%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$42.72M USD+84.6%+27.3%—
Peer median (excluding PRLD) —-13.0%+8.9%889.5%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Depreciation & Amortization915K1.32M1.17M1.77M1.34M
Deferred Income Tax00000
Stock-Based Compensation20.93M25.14M25.62M21.35M11.91M
Change in Working Capital3.63M932K(10.48M)4.22M28.41M
Accounts Receivables00000
Inventory00000
Accounts Payables3.9M(347K)(2.27M)3.31M(3.92M)
Other Working Capital(278K)1.28M(8.21M)911K32.33M
Other Non-Cash Items2.69M4.31M(1.54M)(3.05M)1.53M
Operating Cash Flow(83.53M)(83.73M)(107.06M)(102.89M)(56.3M)
Capital Expenditures(2.32M)(3.02M)(3.51M)(764K)(67K)
Acquisitions (Net)00000
Purchases of Investments(261.48M)(119.22M)(221.63M)(52.69M)(100.87M)
Sales of Investments0203.93M190.5M143.65M154.39M
Other Investing Activities00000
Investing Cash Flow(263.8M)81.69M(34.65M)90.19M53.46M
Debt Repayment000(395K)(208K)
Common Stock Issued161.42M815K135.73M329K25.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.47M0664K(54K)(17K)
Financing Cash Flow164.9M815K136.4M(120K)24.82M
Effect of Forex Changes00000
Net Change in Cash(182.44M)(1.22M)(5.31M)(12.82M)21.97M
Free Cash Flow(85.85M)(86.75M)(110.58M)(103.65M)(56.37M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.